Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Laboratory Biomarker Analysis

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT03453489Phase 2Completed

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

Showing all 1 trials

Research Network

Common Treatments

  • Laboratory Biomarker Analysis1
  • Positron Emission Tomography1
  • Carbon C 11 Alphamethyltryptophan1
  • Telotristat Etiprate1

Active Sponsors

  • Barbara Ann Karmanos Cancer Institute1
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Carcinoid Syndrome1

Activity Timeline